PAVE 100

Phase:
IIb
Status:
Withdrawn
Strategies:
DNA, Viral Vector - Adeno
Candidates:
VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP
Countries:
USA
Volunteers:
0

A test-of-concept clinical trial to evaluate the efficacy, safety, and immunogenicity of a multiclade HIV-1 DNA plasmid vaccine, VRC-HIVDNA016-00-VP, followed by a multiclade recombinant adenoviral vector vaccine, VRC-HIVADV014-00-VP.

IAVI V002

Phase:
II
Status:
Withdrawn
Strategies:
DNA, Viral Vector - Adeno
Candidates:
VRC-HIVDNA016-00-VP, VRC-HIVADV014-00-VP
Countries:
Kenya;Rwanda;Uganda;Zambia
Volunteers:
0

A randomized, placebo-controlled, double-blind trial to evaluate the safety and immunogenicity of a multiclade HIV-1 DNA plasmid vaccine followed by recombinant, multiclade HIV-1 adenoviral vector vaccine.

IAVI B004

Phase:
I
Status:
Completed
Strategies:
DNA, Viral Vector - Adeno
Candidates:
HIV-MAG+GENEVAX® IL-12, Ad35-GRIN/ENV
Countries:
Kenya;Uganda;Rwanda
Volunteers:
75
Partners:
Kenya AIDS Vaccine Initiative (KAVI-Kangemi)-Kangemi, Kenya; Projet San Francisco (PSF-Kigali)-Kigali, Rwanda; Uganda Virus Research Institute-International AIDS Vaccine Initiative (UVRI-IAVI), Entebbe, Uganda; Profectus BioSciences Inc.; Ichor Medical Systems.

IAVI 006

Phase:
I/II
Status:
Completed
Strategies:
DNA; Viral Vector - Pox
Candidates:
DNA.HIVA ; MVA.HIVA
Countries:
United Kingdom
Volunteers:
120
Partners:
John Warin Ward, The Churchill, Headington, Oxford, UK; St. Mary's Hospital, London, UK; Medical Research Council (MRC), Oxford, UK.

Study Summary:
The objectives of this study are to evaluate and compare the safety and immunogenicity of two doses of candidate HIV-1 clade A DNA vaccine versus a placebo (delivered by intramuscular injection) followed by a candidate HIV-1 clade A MVA vaccine or placebo.

IAVI B002

Phase:
I
Status:
Completed
Strategies:
Protein; Viral Vector - Adeno
Candidates:
Adjuvanted GSK investigational HIV vaccine formulation 1; Adjuvanted GSK investigational HIV vaccine formulation 2; Ad35-GRIN
Countries:
Kenya;Uganda;Zambia
Volunteers:
147
Partners:
Kenya AIDS Vaccine Initiative-Kenyatta National Hospital (KAVI-KNH), Nairobi, Kenya; Uganda Virus Research Institute-International AIDS Vaccine Initiative (UVRI-IAVI), Entebbe, Uganda; Medical Research Council (MRC)-Masaka, Uganda; Zambia-Emory HIV Research Project (ZEHRP)-Lusaka, Zambia; GlaxoSmithKline.

The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of an adjuvanted investigational HIV vaccine developed by GlaxoSmithKline and Ad35-GRIN in 4 different regimens at months 1, 2, 3, and 4.